Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

10 May 2016 - 16 May 2016
11 May 2016 - 13 May 2016

Novel Toll-Like Receptor 7 Agonist Suppresses Replication of Hepatitis B Virus in Chimps

By BiotechDaily International staff writers
Posted on 08 May 2013
Print article
An experimental low molecular weight drug that activates the protein Toll-Like Receptor 7 on cells of the immune system was found to suppress viral replication and delay progression of liver disease in chimpanzees chronically infected with hepatitis B virus (HBV).

Toll-Like Receptor 7 normally recognizes invading viruses and signals the immune system to suppress viral replication via the innate immune response and to kill infected cells via the adaptive immune response. The experimental drug GS-620, developed by the biopharmaceutical company Gilead Sciences (Foster City, CA, USA) is a potent and selective orally active small molecule agonist of Toll-like receptor 7.

Investigators from Gilead Sciences and colleagues at Texas Biomedical Research Institute's Southwest National Primate Research Center (San Antonio, USA) administered GS-9620 was to HBV-infected chimpanzees every other day for four weeks and, after a one-week rest, for an additional four weeks at a higher dosage. They measured viral load in plasma and liver samples, the pharmacokinetics of GS-9620, and the following pharmacodynamics parameters: interferon-stimulated gene expression, cytokine and chemokine levels, lymphocyte and natural killer cell activation, and viral antigen expression. Clinical pathology parameters were monitored to determine the safety and tolerability of GS-9620.

Results published in the February 14, 2013, online edition of the journal Gastroenterology revealed that short-term oral administration of GS-9620 provided long-term suppression of serum and liver HBV DNA. Serum levels of HBV surface antigen, HBV e antigen, and numbers of HBV antigen-positive liver cells were reduced as liver cell apoptosis increased. GS-9620 administration induced production of interferon-alpha and other cytokines and chemokines, and activated interferon-stimulated genes, natural killer cells, and lymphocyte subsets.

"This GS-9620 therapy represents the first conceptually new treatment for HBV in more than a decade, and combining it with the existing antiviral therapy could be transformative in dealing with this disease," said first author Dr. Robert E. Lanford, a virologist and immunologist at the Texas Biomedical Research Institute. "This is an important proof-of-concept study demonstrating that the therapy stimulates the immune system to suppress the virus and eliminate infected liver cells. One of the key observations was that the therapy continued to suppress virus levels for months after therapy was stopped."

Related Links:
Gilead Sciences
Texas Biomedical Research Institute


Print article

Channels

Genomics/Proteomics

view channel
Image: A confocal microscopy image of human fibroblasts derived from embryonic stem cells. The nuclei appear in blue, while smaller and more numerous mitochondria appear in red (Photo courtesy of Dr. Shoukhrat Mitalipov, Oregon Health & Science University).

Stem Cells Derived from Older Individuals May Carry Unsafe Mitochondrial DNA Mutations

Induced pluripotent stem cells (iPSCs) derived from the skin fibroblasts of older individuals have a likelihood of harboring mitochondrial DNA mutations, which may render them unfit for clinical applications.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

DNA Synthesis Specialists Acquire Advanced Software Design Capabilities

An American biotech firm that develops and produces synthetic DNA has established an international presence by purchasing an Israeli genetic design software company. Twist Bioscience Corporation (San Francisco, CA, USA), a company specializing in rapid, high-quality DNA synthesis, announced that Genome Compiler Corporation... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.